ESSA Stock Recent News
ESSA LATEST HEADLINES
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=136084&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ESSA Bancorp, Inc. (NasdaqGS: ESSA) to CNB Financial Corporation (NasdaqGS: CCNE). Under the terms of the proposed transaction, shareholders of ESSA will receive 0.8547 shares of CNB for each share of ESSA that they own. KSF is seeking to determine whether this consideration and the process that led.
Investors can contact the law firm at no cost to learn more about recovering their losses
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=135755&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=135743&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX) and certain officers. The class action, filed in the United States District Court for the Eastern District of Wisconsin, and docketed under 25-cv-00124, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK , March 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024.
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=135337&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) and certain officers. The class action, filed in the United States District Court for the Eastern District of Wisconsin, and docketed under 25-cv-00124, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their Options